Clicky

Erasca, Inc(ERAS)

Description: Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.


Keywords: Cancer Biopharmaceutical Acute Myeloid Leukemia Colorectal Cancer Enzymes Non Small Cell Lung Carcinoma Tyrosine Kinase Receptors Nsclc Oncogenes Bemcentinib Metastatic Solid Tumors Ras Gtpase Ptpn11

Home Page: www.erasca.com

ERAS Technical Analysis

10835 Road to the Cure
San Diego, CA 92121
United States
Phone: 858 465 6511


Officers

Name Title
Dr. Jonathan E. Lim M.D. Co-Founder, Chairman & CEO
Mr. Ebun S. Garner J.D., Esq. Gen. Counsel & Corp. Sec.
Dr. Wei Lin M.D. Chief Medical Officer
Dr. Michael D. Varney Ph.D. Chairman of R&D, Scientific Advisory Board Member and Director
Dr. David M. Chacko M.D. Chief Financial Officer
Dr. Nik Chetwyn Ph.D. Sr. VP of Operations
Dr. Lisa Tesvich-Bonora Ph.D. Chief People Officer
Mr. Brian L. Baker CPA, M.S., MS, CPA Sr. VP of Fin.
Ms. Chandra D. Lovejoy Sr. VP of Regulatory Affairs
Dr. Robert Shoemaker Ph.D. Sr. VP of Research

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.9025
Price-to-Sales TTM: 0
IPO Date: 2021-07-16
Fiscal Year End: December
Full Time Employees: 123
Back to stocks